Prognostic Value of Baseline Serum C-Reactive Protein Level in Intermediate-Risk Group Patients With Metastatic Renal-Cell Carcinoma Treated by First-Line Vascular Endothelial Growth Factor-Targeted Therapy

被引：18

作者：

Takamatsu, Kimillaru ^{[1
]}

Mizuno, Ryuichi ^{[1
]}

Omura, Minami ^{[1
]}

Morita, Shinya ^{[1
]}

Matsumoto, Kazuhiro ^{[1
]}

Shinoda, Kazunobu ^{[1
]}

Kosaka, Takeo ^{[1
]}

Takeda, Toshikazu ^{[1
]}

Shinojima, Toshiaki ^{[1
]}

Kikuchi, Eiji ^{[1
]}

Asanuma, Hiroshi ^{[1
]}

Oyama, Masafumi ^{[3
]}

Mikami, Shuji ^{[2
]}

Oya, Mototsugu ^{[1
]}

机构：

[1] Keio Univ Hosp, Dept Urol, Tokyo, Japan

[2] Keio Univ Hosp, Div Diagnost Pathol, Tokyo, Japan

[3] Saitama Med Univ, Dept Urooncol, Int Med Ctr, Hidaka, Japan

来源：

CLINICAL GENITOURINARY CANCER | 2018年 / 16卷 / 04期

关键词：

Biomarker; International Metastatic Renal Cell Carcinoma Database Consortium Model; Kidney cancer; Molecular targeted drug; Prognosis; INTERFERON-ALPHA; CANCER; IMPACT; INFLAMMATION; SUNITINIB; SURVIVAL;

D O I：

10.1016/j.clgc.2018.03.012

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Because accumulating evidence underlines the association of systemic inflammation with metastatic renalcell carcinoma (mRCC) progression, we evaluated baseline C-reactive protein (CRP) levels as a prognostic marker in 107 intermediate-risk mRCC patients treated with first-line targeted therapy. Baseline CRP could be a biomarker correlated with overall survival in the intermediate-risk group. Its cost efficacy and availability make CRP a helpful tool for reclassifying the intermediate-risk group. Background: Almost half of patients with metastatic renal-cell carcinoma (mRCC) are classified as intermediate risk by the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) model. The aim of this study was to evaluate whether baseline C-reactive protein (CRP) levels predict overall survival (OS) in intermediate-risk group mRCC patients. Patients and Methods: Data from 107 intermediate-risk group mRCC patients receiving first-line targeted therapy were retrospectively reviewed. We evaluated the correlation between baseline CRP levels as well as other indices and OS. Results: Of the 107 patients with intermediate-risk disease, 46 patients (43%) were classified as having elevated CRP levels. The elevation of pretreatment serum CRP levels was the independent prognostic factor of OS in patients with intermediate risk (hazard ratio, 4.609; P = .001). The 1- and 3-year survival rates of patients with intermediate-nonelevated CRP were 90.0% and 64.7% compared to the favorable-risk group, at 92.1% and 68.5%, respectively. In contrast, the 1 - and 3-year survival rates of patients with intermediate-elevated CRP were 80.5% and 37.4% compared to the poor-risk group, at 65.2% and 24.2%, respectively. Conclusion: Baseline CRP levels could divide mRCC patients in the intermediate-risk group into 2 prognostic subgroups.

引用

页码：E927 / E933

页数：7